Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre

Moss, Ingrid Bandeira; Moss, Monique Bandeira; Reis, Debora Silva dos; Coelho, Reno Martins

doi:10.1016/j.rbre.2014.03.004

Cited by 8 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Initially proposed for toxicity related to anti-cancer therapy, the NCI scale has become a cross-field standard in the drug toxicity communication. 14 , 41 The reactions are divided into five severity grades, ranging from: mild [requires observation only]; through moderate [minimal—usually oral—intervention suffices]; and severe [vital organ involved yet not in life-threatening manner; usually requires parenteral medication]; to life-threatening [multi-system involvement of vital organs, urgent and critical care required]; and death. In terms of immediate infusion reactions, the examples can include: transient flushing or rash [mild reaction]; urticaria/myalgia/drug fever [moderate reaction]; bronchospasm/angioedema/hypotension [severe reaction]; and systemic anaphylactic reaction [life-threatening reaction].…”

Section: Terminology and Nomenclaturementioning

confidence: 99%

Infliximab-Related Infusion Reactions: Systematic Review

Lichtenstein

Ron

Kivity

et al. 2015

ECCOJC

199

134

View full text Add to dashboard Cite

Objective:Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusion reactions to infliximab, and for controlling the reactions once they occur.Methods:We conducted extensive search of electronic databases of MEDLINE [PubMed] for reports that communicate various aspects of infusion reactions to infliximab in IBD patients.Results:We examined full texts of 105 potentially eligible articles. No randomised controlled trials that pre-defined infusion reaction as a primary outcome were found. Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analysis; and 62 additional studies focused on various aspects of mechanism/s, risk, primary and secondary preventive measures, and management algorithms. Seven studies were added by a manual search of reference lists of the relevant articles. A total of 76 original studies were included in quantitative analysis of the existing strategies.Conclusions:There is still paucity of systematic and controlled data on the risk, prevention, and management of infusion reactions to infliximab. We present working algorithms based on systematic and extensive review of the available data. More randomised controlled trials are needed in order to investigate the efficacy of the proposed preventive and management algorithms.

show abstract

Section: Terminology and Nomenclaturementioning

confidence: 99%

Infliximab-Related Infusion Reactions: Systematic Review

Lichtenstein

Ron

Kivity

et al. 2015

ECCOJC

199

134

View full text Add to dashboard Cite

show abstract

“…Применение инфликсимаба под тщательным клиническим наблюдением считается относительно безопасным, хотя и не исключает развитие различных нежелательных реакций, в том числе активацию оппортунистических инфекций, дополнительную активацию цитокинового шторма, анафилактических реакций, формирование гиперчувствительности замедленного типа и др. [47,56,57].…”

Section: тоцилизумабunclassified

Some opportunities for immunotherapy in coronavirus infection

Смирнов

Тотолян

2020

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Here we review means of immunomodulatory therapy for coronavirus infection caused by SARS-CoV-2 (COVID-19). It has been appreciated that highly limited arsenal of relatively effective means and methods of prevention and treatment of the COVID-19 pandemic is available. The goal of our study was to analyze some therapeutic approaches based on available publications for COVID-19 treatment viewed from acting via innate immunity system. Convalescent plasma serotherapy represents one of the means with verified therapeutic efficacy that was accompanied with decreased viral load and relief of the disease symptoms. The drawback of serotherapy results from limited number of potential plasma donors and profound variety in amount of SARS-CoV-2-specific antibodies found in donor plasma. Another approach to COVID-19 therapy is based on using monoclonal antibodies engineered to target specific virus antigenic determinants, most often surface spike antigen. Antibodies blocking such antigen are able to prevent virus entrance into target cells and development of overt infection. On the other hand, there are monoclonal antibodies abrogating production or binding of excessive amounts of pro-inflammatory cytokines, such as IL-6, TNFα, etc., some of which (tocilizumab) have been already tested in COVID-19 therapy, whereas the remaining preparations are being currently investigated and tested. A certain breakthrough in COVID-19 therapy was provided by the well-known drugs chloroquine and dihydrochloroquine, which have proven to be effective as antiviral, anti-inflammatory and immunomodulatory means. Finally, a new multicomponent immunomodulatory preparation Cytovir-3 has been proposed already passed clinical trials and recommended for use in prevention and treatment of influenza and SARS and might have found its own niche in preventing COVID-19, as SARS-CoV-2 also belongs to the group of acute respiratory viruses. Thus, the arsenal of means for COVID-19 prevention and treatment contains the drugs for immunomodulatory therapy and prevention of immune-related disorders developing in response to invasion pathogenic viruses and lowering a risk of possible damage. Hence, correct and scientifically justified use of such remedies will increase overall effectiveness of fight against the coronavirus pandemic.

show abstract

“…1 Although IRs have been reported to develop in 3-22% of psoriatic patients, 1,3 there is no evidence that premedication decreases the rate of this adverse effect. 3 Moreover, the optimal premedication strategy has not yet been established. 4 We report the retrospective experience of three Italian Psoriasis Centres on a total of 42 patients, treated with infliximab from 2006 through 2015 for plaque psoriasis, who were never pretreated or else stopped the premedication after some infusions.…”

mentioning

confidence: 99%

“…1 Although the antibody formation seems to decrease with the use of premedication, most part of rheumatological and gastroenterological studies agree that pretreatment is not associated with a lower rate of IRs. 3,4,6 However, no dermatological studies have been conducted so far.…”

mentioning

confidence: 99%

“…The outer root sheath (ORS) of the hair follicle (HF) has a similar expression pattern to that of the epidermal keratinocyte, with Dsg1 expressed in the inner layers and Dsg3 expressed in all extensions. 2,3 Furthermore, scalp involvement may be a potential risk factor for clinical complications. 4 Our study included 38 patients, 20 diagnosed with pemphigus foliaceus (PF) and 18 with pemphigus vulgaris (PV) with active…”

mentioning

confidence: 99%

See 1 more Smart Citation